To estimate the net cost of asthma to NC Medicaid and identify factors influencing the health care cost of asthmatics. METHODS: The study design was a retrospective matched case control design wherein administrative claims data from NC Medicaid spanning May 1996 through April 1998 were utilized. Inclusion criteria were: at least one inpatient claim for asthma (ICD-9-CM = 493) or 2 or more outpatient asthma claims or asthma prescriptions in the first year. Exclusion criteria were: a diagnosis for emphysema, COPD, cancer, age <1 and age >65, a nursing home claim, or prescription for Ipratropium in the first year. A sensitivity analysis using case definitions restricted to diagnosis or drug markers was also undertaken. To estimate net costs, non-asthmatic comparison subjects were matched 1 : 1 on age, gender, and race. Net adjusted cost differences were obtained from a generalized least square (GLS) model accounting for heteroscedasticity with terms to account for unmatched factors. To investigate factors influencing asthma costs, separate GLS models exploring 40 different comorbidity categories, demographics were estimated for all asthmatics. RESULTS: The net cost for asthma was $910 (CI: 787 to 1032, N = 27,493) with prescriptions (33%), hospitalizations (14%) comprising a majority of costs. The net cost of asthma was not meaningfully affected by varying case definitions but prevalence estimates varied between 2.2% to 4.6%. In the asthma group, asthmatics with congestive heart failure ($3232), psychoses ($3128), diabetes ($2143), depression ($1363), and lower respiratory tract infections ($416) were among the most influential comorbidity drivers of total cost (p < 0.001). Males ($486) and whites ($835) had higher costs than their counterparts (p < 0.001). For prescription and physician costs, diseases such as hypertension, rhinitis, and sinusitis were also influential (p < 0.001). CON-CLUSION: The net cost of asthma is estimated at $900/year above a comparable non-asthmatic Medicaid recipient. The cost of asthma is driven by prescriptions, hospitalizations and is greatly affected by several comorbidities which should be considered when delivering care for asthmatics.
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OBJECTIVES:
The combination drug, fluticasone propionate and salmeterol (FPS), and zafirlukast, a leukotriene receptor antagonist (LTRA), represent two classes of asthma controller medications. FPS has been shown to be more clinically effective compared to drugs in the LTRA group. Our objective is to determine the financial benefits associated with managing severe adult asthma with FPS or zafirlukast, from a self-insured employer's perspective. METHODS: We developed a Markov model to predict the health outcomes and costs for asthma in a hypothetical, commercially insured population. The model predicts asthma costs of hospitalizations, pharmacy, professional visits, and outpatient services. It also estimates non-medical costs using lost workdays due to asthma. We used $2.40 as the plan's net cost per patient per day for FPS and $1.48 for zafirlukast. The beneficial effects of each drug are modeled by a reduction in health service utilization and lost workdays. The model assumes that all severe adult asthma patients not well managed at baseline are optimally managed in the intervention scenario, with 100% medication compliance. The costbenefit is expressed as net savings in medical and nonmedical costs. RESULTS: For a commercially insured population of 100,000 members, the model predicted 276 severe adult asthma cases, and net savings of $0.13 per member per month (PMPM) over 3 years for FPS. Zafirlukast is estimated to take more than three years to break even. For both drugs, about 46% of total savings are from non-medical savings. A sensitivity analysis shows that FPS continues to be cost beneficial over 3 years as long as the medication compliance is 63% or more. CONCLUSIONS: Managing adult severe asthma with FPS is predicted to be cost-beneficial in the short term from a self-insured employer's perspective.
